Strong Revenue Growth
Enterprise revenue reached $3.5 billion, representing 10% growth year-over-year. Diagnostics revenue grew 9%, reaching $2.7 billion, driven equally by organic growth and acquisitions.
Biopharma Laboratory Services Performance
BLS delivered strong revenue performance, growing 11% or 8% constant currency to $785 million, with margins improving by 50 basis points.
New and Innovative Test Launches
Launched new tests in specialty areas including oncology and Alzheimer's. Key launches include Labcorp Plasma Detect and PGDx elio plasma focus Dx for cancer detection and monitoring.
Improved Financial Metrics
Adjusted earnings per share of $4.35 grew 10% year-over-year. Operating cash flow was $621 million compared to $561 million a year ago, with a $110 million increase in free cash flow.
Raised Full Year Guidance
Raised 2025 full year guidance for enterprise revenue, adjusted EPS, and free cash flow, driven by currency and underlying business strength.